Skip to content

Gastric Neuroendocrine Tumor G1 C0349529

Published: July 22, 2026Updated: August 20, 2026

A slow-growing tumor that forms in the stomach from hormone-producing cells. These low-grade tumors are relatively uncommon but generally have a favorable outlook. Treatment typically involves surgery and may include medications to control tumor growth.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C80.1
ICD-11
2A00.0
Body system
oncologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Epigastric pain

(oncologic)

Generalized symptoms

(oncologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Dyspepsia

(oncologic)

Flushing

(oncologic)

Carcinoid syndrome

(oncologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Endoscopic Mucosal Resection

Minimally invasive endoscopic technique for complete removal of localized gastric NET G1 lesions. This approach preserves the stomach and offers excellent outcomes for small, superficial tumors with low malignant potential.

procedure
2

Lifestyle modification and dietary intervention

Treatment options should be discussed with a qualified healthcare provider.

lifestyle

Additional treatment options

Somatostatin Analog Therapy

Long-acting somatostatin analogs such as octreotide or lanreotide to control hormone-related symptoms and potentially slow tumor progression. Particularly useful for functioning tumors with carcinoid syndrome features.

medication

Partial Gastrectomy

Surgical removal of a portion of the stomach containing the neuroendocrine tumor, recommended for larger lesions or those not amenable to endoscopic resection. May be performed laparoscopically for eligible patients.

surgical

Serial Endoscopic Surveillance

Regular upper endoscopy with endoscopic ultrasound for close monitoring of tumor characteristics, recurrence detection, and assessment of regional lymph nodes. Frequency determined by initial tumor stage and resection completeness.

monitoring

Tumor-Promoting Factor Avoidance Diet

Dietary modifications focusing on reduced intake of processed foods, alcohol, and foods that may stimulate gastric acid production. Emphasis on antioxidant-rich whole foods to support overall gastrointestinal health.

dietary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Gastric Neuroendocrine Tumor G1 C0349529?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Delle Fave G, O'Toole D, Sundin A, et al. ENETS Consensus Guidelines for Gastric Neuroendocrine Tumors. Neuroendocrinology. 2020;111(1-2):1-20.

guideline2020
2

Modlin IM, Oberg K, Chung DC, et al. Gastrointestinal Neuroendocrine Tumors: Current Diagnosis and Management. Gastroenterology. 2018;154(4):1042-1059.

review2018
3

Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term Outcomes After Surgical Resection of Gastric Neuroendocrine Tumors. Ann Surg Oncol. 2019;26(5):1480-1487.

clinical_trial2019
4

Xie R, Chen KM, Sun J, et al. Clinical Outcomes and Prognostic Factors in Gastric Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Eur J Cancer. 2021;144:320-333.

meta_analysis2021

Medication Comparisons

Compare medications used to treat Gastric Neuroendocrine Tumor G1 C0349529. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy